Clinical trials: Sarcoidosis
Cutaneous Sarcoidosis
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
- Trial name
- BEACON (NCT06978725)
- Testing
- Oral Brepocitinib
- Where
- 39 sites in United States
- Volunteers
- 168 people
- Sponsor
- Priovant Therapeutics, Inc.
Pulmonary Sarcoidosis
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
A study of XTMAB-16 in patients with pulmonary sarcoidosis
- Trial name
- NCT07680166
- Testing
- XTMAB-16
- Volunteers
- 182 people
- Sponsor
- Xentria, Inc.
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.
Cystic Fibrosis, Pulmonary Fibrosis
Role of Genetic Factors in the Development of Lung Disease
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.
- Conditions
- Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma
- Trial name
- NCT00001532
- Where
- 2 sites in United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sarcoidosis
Prognostic Value of Clinical Cardiovascular MRI
The primary objective of this study is to identify findings on cardiovascular MR imaging (CMR) that are specific to various cardiac or vascular disorders in patients undergoing routine CMR scans.
- Trial name
- NCT01745237
- Where
- United States
- Volunteers
- 27,000 people
- Sponsor
- Duke University
Pulmonary Sarcoidosis
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
- Trial name
- NCT06169397
- Testing
- XTMAB-16
- Where
- 11 sites in United States, Czechia and 2 more
- Volunteers
- 31 people
- Sponsor
- Xentria, Inc.
Sarcoidosis, Pulmonary
Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis
The goal of this clinical trial is to learn whether a study drug called Compound Betamethasone (also known as Diprospan) works to treat pulmonary sarcoidosis in people with early-stage disease (stage I or II).
- Trial name
- NCT07668895
- Testing
- Prednisone, Compound betamethasone
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Peking Union Medical College Hospital
Acute Cellular Graft Rejection, Cardiac Sarcoidosis
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute…
- Conditions
- Acute Cellular Graft Rejection, Cardiac Sarcoidosis, Myocarditis Due to Drug
- Trial name
- NCT05499637
- Testing
- [68Ga]Ga-PentixaFor PET/CT
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- John O. Prior
Pulmonary Sarcoidosis
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS). This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS.
- Trial name
- NCT07867938
- Testing
- Tulisokibart, Background prednisone therapy
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Sarcoidosis
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects…
- Trial name
- NCT06205121
- Testing
- OATD-01
- Where
- 28 sites in United States, Denmark and 6 more
- Volunteers
- 96 people
- Sponsor
- Molecure S.A.
Interstitial Lung Disease
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area.
- Trial name
- GAZEBO-ILD (NCT07859839)
- Testing
- Gabapentin, Benzonatate 200 mg, Standard of care treatment for ILD
- Where
- India
- Volunteers
- 177 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Sarcoidosis
Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis
The goal of the current study is to evaluate the potential of the selected PET tracers to detect sarcoidotic lesions in lungs. The tracers are already in clinical use for the detection of certain inflammatory processes or…
- Trial name
- NCT02824419
- Testing
- Methionine, DOTANOC
- Where
- Finland
- Volunteers
- 5 people
- Sponsor
- Turku University Hospital
Pulmonary Sarcoidosis
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
- Trial name
- NCT05890729
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 32 people
- Sponsor
- Xentria, Inc.
Cardiac Sarcoidosis
Cardiac Sarcoidosis Multi-Center Prospective Cohort
Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon.
- Trial name
- CHASM-CS (NCT01477359)
- Where
- 14 sites in Canada, Japan
- Volunteers
- 1,500 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Sarcoidosis
Janus Kinase Inhibition in Sarcoidosis
The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.
- Trial name
- NCT05696795
- Testing
- Abrocitinib 200 mg
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Cardiac Sarcoidosis, Infective Endocarditis
A Prospective Diagnostic Trial of Al[¹⁸F]F-NOTA-folate PET in Patients With Suspected Cardiac Sarcoidosis and Infective Endocarditis
The goal of this prospective diagnostic study is to evaluate the imaging characteristics, diagnostic performance, radiation dosimetry, and safety of Al[¹⁸F]F-NOTA-folate PET imaging in patients with suspected cardiac sarcoidosis…
- Trial name
- FOL-CARD (NCT07814222)
- Testing
- Al[¹⁸F]F-NOTA-folate PET imaging, [15O]water PET imaging, Echocardiography
- Where
- Finland
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Sarcoidosis, Pulmonary
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year).
- Trial name
- CAESAR (NCT05841758)
- Testing
- Hydroxychloroquine
- Where
- 21 sites in France
- Volunteers
- 140 people
- Sponsor
- Hospices Civils de Lyon
Sarcoidosis, Vitamin D Insufficiency
Vitamin D Homeostasis in Sarcoidosis
This study evaluates the relationship between vitamin-D status and severity of sarcoidosis, and the effects of vitamin-D repletion in vitamin-D insufficient patients with sarcoidosis.
- Trial name
- NCT03621553
- Testing
- Ergocalciferol, Calcium Citrate with Vitamin D2
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Texas Southwestern Medical Center
Uveitis
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
Background: Uveitis is a serious eye disease that can cause vision loss. Treatment sometimes causes serious side effects or does not work. Researchers want to learn more about uveitis and why some people develop it.
- Trial name
- NCT02656381
- Where
- United States
- Volunteers
- 343 people
- Sponsor
- National Eye Institute (NEI)
Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy, Cardiac Sarcoidosis, Hypertensive Heart Disease
- Trial name
- CHIEFTain (NCT06409585)
- Testing
- 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh